<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Myocardial ischemic conditioning: Pathogenesis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Myocardial ischemic conditioning: Pathogenesis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Myocardial ischemic conditioning: Pathogenesis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Derek J Hausenloy, MD, PhD, FRCP, FACC, FESC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Derek M Yellon, PhD, DSc, Hon FRCP, FACC, FESC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The myocardium possesses adaptive mechanisms that render it resistant to potentially lethal ischemia and reperfusion injury. (See  <a class="medical medical_review" href="/d/html/1511.html" rel="external">"Reperfusion injury of the heart", section on 'Definition'</a>.)</p><p>Myocardial ischemic conditioning refers to interventions that protect the heart from injury due to exposure to prolonged ischemia. The conditioning may be delivered before, during or after the prolonged ischemic insult. Other protective mechanisms include the long-term development of coronary collateral vessels, and myocardial hibernation and stunning. (See  <a class="medical medical_review" href="/d/html/1523.html" rel="external">"Coronary collateral circulation"</a> and  <a class="medical medical_review" href="/d/html/1516.html" rel="external">"Pathophysiology of stunned or hibernating myocardium"</a>.)</p><p>The definition and pathogenesis of ischemic preconditioning and postconditioning will be reviewed here. The clinical implications of these phenomena in the human myocardium and possible future therapeutic applications are discussed separately. (See  <a class="medical medical_review" href="/d/html/1489.html" rel="external">"Myocardial ischemic conditioning: Clinical implications"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ISCHEMIC PRECONDITIONING</span><span class="headingEndMark"> — </span>Myocardial ischemic preconditioning refers to the protection conferred to ischemic myocardium by brief periods of sublethal ischemia separated by periods of short bursts of reperfusion delivered before the ischemic insult [<a href="#rid1">1</a>]. It provides the myocardium with a powerful means of protecting against acute myocardial ischemia. </p><p>Ischemic preconditioning has been reproducibly demonstrated in all animal species studied as well as humans [<a href="#rid1">1-5</a>]. It may occur as part of some naturally occurring ischemic syndromes [<a href="#rid6">6</a>]. Furthermore, in addition to enhanced tolerance to lethal cell injury, preconditioning is protective against other end points of ischemia-reperfusion injury, including postischemic contractile dysfunction [<a href="#rid7">7</a>] and ischemia- and reperfusion-induced ventricular arrhythmias [<a href="#rid8">8,9</a>]. Ischemic preconditioning also decreases apoptosis in animals, another mechanism that can contribute to cell death after myocardial ischemia and reperfusion [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/1511.html" rel="external">"Reperfusion injury of the heart", section on 'Apoptosis'</a>.)</p><p>The protection afforded by ischemic preconditioning is apparent immediately after the preconditioning ischemia, but is short-lived and wanes after one to two hours [<a href="#rid11">11,12</a>]. After 12 to 24 hours following the preconditioning ischemia, a delayed phase of myocardial protection is induced that, although not as powerful as the early phase, is more prolonged and lasts up to 72 hours [<a href="#rid13">13-15</a>]. This delayed phase of resistance to ischemic injury has been termed the "second window of protection" [<a href="#rid16">16</a>], distinguishing it from early or "classic" preconditioning.</p><p>Most laboratory studies of ischemic preconditioning have been performed in animals with "normal" hearts; these observations do not necessarily permit conclusions about the influence of coexisting pathology [<a href="#rid17">17</a>]. Preclinical (animal and human) studies have shown that the threshold for protection in co-morbid settings such as diabetes and age is raised and although it is still possible to protect the myocardium, it requires a stronger conditioning stimulus [<a href="#rid18">18-20</a>]. More experiments have shown that hypertrophied myocardium is amenable to preconditioning [<a href="#rid21">21,22</a>]. Some reports have found that the preconditioning response is conserved in senescent myocardium [<a href="#rid23">23</a>], while others have not [<a href="#rid24">24,25</a>]. However, the demonstration of cardioprotection by preconditioning in the clinical setting suggests that patients with ischemic heart disease are amenable to preconditioning. (See  <a class="medical medical_review" href="/d/html/1489.html" rel="external">"Myocardial ischemic conditioning: Clinical implications"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Duration</span><span class="headingEndMark"> — </span>The reduction in infarct size resulting from ischemic preconditioning is a graded phenomenon. A threshold must be reached during preconditioning ischemia to achieve protection during prolonged ischemia. In one animal study, ischemia lasting less than two minutes did not reduce infarct size, even when there were multiple cycles of ischemia; in contrast, infarct size was significantly and progressively reduced by a single ischemic episode lasting 3 or 10 minutes (infarct size 17 percent without ischemic preconditioning versus 9 and 2 percent with 3 and 10 minutes of ischemic preconditioning, respectively) [<a href="#rid26">26</a>]. In other studies, extending the duration of preconditioning ischemia beyond 10 minutes abolished the protection or even has deleterious consequences during the prolonged ischemia [<a href="#rid27">27,28</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Mediators</span><span class="headingEndMark"> — </span>The mechanisms underlying ischemic preconditioning have not been completely elucidated  (<a class="graphic graphic_algorithm graphicRef71019" href="/d/graphic/71019.html" rel="external">algorithm 1</a>) [<a href="#rid29">29</a>]. A number of early theories for the preconditioning effect have been thoroughly investigated and ruled out, including recruitment of collateral vessels [<a href="#rid1">1,2,5,30,31</a>], myocardial stunning [<a href="#rid32">32</a>], or depletion of glycogen [<a href="#rid31">31,33,34</a>]</p><p>Considerable progress has been made toward the identification of potential cell triggers, intracellular signaling cascades, and end-effectors involved in ischemic preconditioning [<a href="#rid35">35,36</a>]. There are several lines of evidence suggesting a role for endogenous paracrine mediators, released during the brief period of ischemia and acting on local receptors, as triggers of ischemic preconditioning. Various models of preconditioning in different species have implicated the involvement of substances such as adenosine [<a href="#rid2">2</a>], acetylcholine [<a href="#rid37">37</a>], catecholamines [<a href="#rid38">38</a>], angiotensin II [<a href="#rid39">39</a>], bradykinin [<a href="#rid40">40</a>], endothelin [<a href="#rid41">41</a>], opioids [<a href="#rid42">42</a>], and reactive oxygen species [<a href="#rid43">43</a>].</p><p>The relative importance of the mediators may vary with the duration of preconditioning ischemia and timing. In one study, for example, bradykinin was essential when preconditioning ischemia lasted for three minutes while adenosine is more important during preconditioning ischemia lasting 10 minutes [<a href="#rid26">26</a>].</p><p>There appears to be an additive interaction of individual preconditioning triggers to achieve the protective threshold. This was illustrated in a report using human atrial muscle in which two individual triggers (a subthreshold hypoxic insult and elevated bradykinin levels by angiotensin converting enzyme inhibition) were insufficient to induce preconditioning when administered separately but, in combination, produced a full protective effect [<a href="#rid44">44</a>].</p><p>With respect to the time at which mediators of ischemic preconditioning act, mediators such as adenosine and protein kinase C are released or activated in response to the preconditioning stimulus and therefore act prior to or during the index ischemic period. In contrast, reactive oxygen species and prosurvival kinases act both prior to the index ischemic period and at the time of reperfusion after the index ischemic period, while inhibition of opening of the mitochondrial permeability transition pore occurs only during reperfusion.</p><p>Mediators of ischemic preconditioning likely lead to intracellular changes that protect individual myocytes from ischemic reperfusion injury. A cascade of intracellular kinases and subsequent modifications of mitochondrial function, though opening of adenosine triphosphate-sensitive potassium channels and closure of mitochondrial permeability transition pores, have been observed [<a href="#rid45">45,46</a>]. </p><p class="headingAnchor" id="H6"><span class="h3">Adenosine</span><span class="headingEndMark"> — </span>The relative importance of the triggers implicated in preconditioning seems to be dependent upon the species and the end point of ischemia-reperfusion injury studied. Adenosine, an endogenous compound formed from the breakdown of adenosine triphosphate (ATP) in myocytes during periods of ischemia has been consistently shown to be involved in triggering preconditioning in most animal species studied, including humans [<a href="#rid47">47</a>]. An inability to produce adenosine endogenously is associated with refractoriness of the myocardium to ischemic preconditioning while stimulation of myocardial adenosine A1 receptors by an exogenously administered agonist re-induces cardioprotection of preconditioning [<a href="#rid48">48</a>]. Furthermore, the myocardium can be maintained in a preconditioned state against ischemia-reperfusion by repeated activation of the adenosine A1 receptor over a 10-day period, without the development of tachyphylaxis [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Protein kinase C</span><span class="headingEndMark"> — </span>A number of these triggers, such as adenosine, norepinephrine, acetylcholine, and bradykinin, are coupled to pertussis toxin sensitive inhibitory G-proteins (Gi). It has been proposed that activation of these Gi-protein coupled receptors by various ligands results in activation of a number of kinase cascades at the center of which lies protein kinase C (PKC) [<a href="#rid50">50</a>].</p><p>One animal study reported that a small increase in intracellular calcium concentration that results from myocardial ischemia and reperfusion can also activate PKC [<a href="#rid51">51</a>]. In another report, a brief intracoronary infusion of <a class="drug drug_general" data-topicid="9186" href="/d/drug information/9186.html" rel="external">calcium chloride</a> mimicked infarct size reduction seen with preconditioning; this effect could be blocked by an inhibitor of calcium influx [<a href="#rid52">52</a>]. Activation of PKC can occur by alpha adrenoreceptor stimulation during ischemic preconditioning and this also requires calcium [<a href="#rid53">53</a>]. This group of enzymes is therefore thought to be an important intermediate in the signal transduction pathway of ischemic preconditioning, resulting in phosphorylation and activation of possible end-effector(s).</p><p>A number of subsequent studies supported this hypothesis. Ischemic preconditioning is blocked by pretreatment with specific PKC inhibitors [<a href="#rid53">53,54</a>] and the substitution of preconditioning ischemia with PKC activators mimics the infarct-limiting effects of ischemic preconditioning [<a href="#rid54">54</a>]. The time course of classic preconditioning also parallels the transient translocation of PKC to the sarcolemmal membrane following activation that lasts for about 60 minutes. Which PKC isoenzyme(s) are activated during preconditioning ischemia is not known. </p><p>It is also likely that other protein kinases, in parallel with or following activation by PKC, may play a role in classic ischemic preconditioning. Activation of tyrosine protein kinases may be a crucial step in the signaling cascade since genistein, a selective tyrosine kinase inhibitor, abolishes the protective effects of preconditioning [<a href="#rid55">55</a>]. Protein kinase A has also been implicated [<a href="#rid56">56</a>]. The relative positions of PKC, tyrosine kinase, and other kinases in the signal transduction pathway of ischemic preconditioning are currently under investigation. Tyrosine kinase may be downstream of PKC and tyrosine phosphorylation may activate a member of the mitogen activated protein kinase (MAPK) family [<a href="#rid55">55,57</a>].</p><p class="headingAnchor" id="H8"><span class="h3">ATP-dependent potassium channels</span><span class="headingEndMark"> — </span>ATP-dependent potassium channels (KATP) appear to be involved in the metabolic adaptation to ischemia seen during preconditioning [<a href="#rid58">58</a>]. There is evidence that mitochondrial KATP channels rather than surface sarcolemmal KATP channels are the likely effectors [<a href="#rid59">59,60</a>]. Opening of these channels results in a repolarizing current that reduces the duration of the cardiac action potential, leading to reduced calcium entry into the myocyte [<a href="#rid61">61</a>]. This results in a reduction in cardiac workload, an enhancement of myocardial viability, and a reduction in cardiac sympathetic nerve injury [<a href="#rid62">62</a>].</p><p>The potential importance of these channels can be illustrated by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>In an experimental model, the transfer of cardiac KATP channel subunits to KATP channel-deficient cells resulted in protection from hypoxia-reoxygenation [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dysfunction of the mitochondrial KATP channel may be responsible for the failure to precondition the diabetic heart [<a href="#rid64">64</a>].</p><p></p><p>The KATP channels may interact with the other mediators described above. PKC activates these channels in human and rabbit ventricular myocytes [<a href="#rid65">65</a>], and there may be synergistic action of adenosine and PKC on KATP channels and shortening of action potential duration [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/895.html" rel="external">"Cardiac excitability, mechanisms of arrhythmia, and action of antiarrhythmic drugs"</a>.) Further support for the interaction between these factors comes from one study that found that adenosine receptor activation primes the opening of mitochondrial KATP channels in a PKC-dependent manner [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Opioid receptors</span><span class="headingEndMark"> — </span>The activation of delta opioid receptors within cardiac myocytes triggers ischemic preconditioning in animal models and in human atrial tissue [<a href="#rid68">68</a>]; their stimulation mimics ischemic preconditioning while their blockade abolishes it [<a href="#rid69">69-71</a>]. The opioid receptors are coupled to G(i/o) proteins and can activate PKC and mitochondrial KATP channels [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Reactive oxygen species</span><span class="headingEndMark"> — </span>In response to a preconditioning stimulus, the mitochondrial production of reactive oxygen species (ROS) [<a href="#rid73">73</a>], prior to the index ischemic period, acts as a mediator of the preconditioning signal through the activation of various protein kinases such as PKC [<a href="#rid43">43</a>], extracellular-signal regulated kinases (Erk1/2) [<a href="#rid74">74</a>], and p38 MAPK [<a href="#rid55">55,75</a>].</p><p>The following observations illustrated the importance of ROS in preconditioning:</p><p class="bulletIndent1"><span class="glyph">●</span>The preconditioning stimulus can induce mitochondrial release of ROS [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exogenous ROS can mimic the protective effect of ischemic preconditioning [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of an antioxidant during the preconditioning phase can diminish the degree of protection [<a href="#rid43">43,77</a>].</p><p></p><p>On the other hand, reducing oxidative stress normally generated during reperfusion may be protective [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H11"><span class="h3">Prosurvival kinases</span><span class="headingEndMark"> — </span>Signaling through the prosurvival, phosphatidyl inositol 3-OH kinase (PI3K)-Akt cascade [<a href="#rid79">79-81</a>] and ERK1/2 [<a href="#rid82">82,83</a>] during the preconditioning phase appears to contribute to the protective effect of ischemic preconditioning with further suggestions that specific isoforms of P13K, ie, PI3Ka, play a direct cardioprotective role [<a href="#rid84">84</a>]. Signaling through this pathway then results in the activation of endothelial nitric oxide synthase, opening of the mitochondrial KATP channel [<a href="#rid85">85</a>], and cardioprotection due to the mitochondrial generation of ROS [<a href="#rid85">85</a>].</p><p>Prosurvival kinases such as Akt and ERK1/2 also appear to contribute to ischemic preconditioning protection at the time of reperfusion, termed the Reperfusion Injury Salvage Kinase (RISK) pathway [<a href="#rid82">82</a>], acting in part by inhibition of mitochondrial permeability transition pore (MPTP) opening [<a href="#rid86">86,87</a>].</p><p>An alternative cardioprotective signaling pathway recruited at the time of reperfusion that has been shown to contribute to IPC has been described. Termed the Survivor Activating Factor Enhancement (SAFE) pathway, this cascade involves TNF-α and the JAK-STAT3 pathway, and also appears to terminate on the mitochondrial permeability transition pore (MPTP) [<a href="#rid88">88</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Inhibition of MPTP opening</span><span class="headingEndMark"> — </span>It has been proposed that a common pathway for ischemic preconditioning, PKC activation, and mitochondrial KATP channel opening to protect the myocardium occurs via inhibition of MPTP opening during reperfusion, thereby preventing uncoupling of the mitochondria [<a href="#rid86">86,87</a>]. The MPTP is a nonspecific channel of the inner mitochondrial membrane that opens during the first few minutes of postischemic reperfusion [<a href="#rid89">89</a>], and is a critical determinant of both apoptotic and necrotic cell death in the setting of ischemia-reperfusion injury [<a href="#rid90">90</a>]. Inhibition of MPTP opening with ischemic preconditioning is believed to be mediated by activation of the prosurvival kinases [<a href="#rid86">86,87</a>].</p><p class="headingAnchor" id="H13"><span class="h3">Second window of protection</span><span class="headingEndMark"> — </span>The triggers and signaling pathways mentioned above have also been implicated in the delayed phase (second window) of ischemic preconditioning [<a href="#rid16">16</a>]. In animals, preconditioning induces late protective effects against endothelial injury after ischemia and reperfusion [<a href="#rid91">91</a>].</p><p>As with classic preconditioning, the specific triggers and mediators involved depend upon the species and the end points studied. As an example, adenosine is an important trigger for the delayed protection against myocardial infarction in the rabbit and rat [<a href="#rid92">92,93</a>]. In a study in rats, adenosine A1 receptor activation induced delayed myocardial protection, mediated by the mitochondrial antioxidant manganese superoxide dismutase [<a href="#rid93">93</a>].</p><p>In contrast, delayed preconditioning against stunning, originally described in the pig heart, involves free radicals and increased formation of nitric oxide via the inducible form of nitric oxide synthase [<a href="#rid94">94,95</a>], but not adenosine [<a href="#rid96">96,97</a>]. Nitric oxide directly activates the mitochondrial, but not sarcolemmal, KATP channels; this provides a link between nitric oxide-induced cardioprotection and the KATP channels [<a href="#rid98">98</a>]. The delayed antiarrhythmic effect following preconditioning in the canine myocardium is abolished by pretreatment by <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, an effect that may be due to inhibition of nitric oxide or products of the cyclooxygenase pathway [<a href="#rid99">99</a>].</p><p>Further evidence for a role of the cyclooxygenase pathway in the second window of protection comes from studies in rabbits showing that delayed ischemic preconditioning induces upregulation of cyclooxygenase-2 (COX-2), leading to increased prostaglandin synthesis in the myocardium [<a href="#rid100">100,101</a>]; COX-2 upregulation may be mediated by nitric oxide [<a href="#rid102">102</a>]. Administration of selective COX-2 inhibitors in this rabbit model abolishes both the increase in tissue prostaglandins and the cardioprotective effects of ischemic preconditioning [<a href="#rid100">100,101</a>]; this observation has implications for the use of COX-2 inhibitor therapy in patients with ischemic heart disease. (See  <a class="medical medical_review" href="/d/html/1489.html" rel="external">"Myocardial ischemic conditioning: Clinical implications", section on 'Therapeutic applications'</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">ISCHEMIC POSTCONDITIONING</span><span class="headingEndMark"> — </span>Ischemic postconditioning refers to the ability of a series of brief occlusions of either the coronary or peripheral arterial circulation after a severe ischemic insult to protect against ischemic reperfusion injury of the myocardium. </p><p>In animal models, ischemic postconditioning (using the coronary circulation) is almost as effective as ischemic preconditioning and involves similar pathogenetic mechanisms [<a href="#rid103">103,104</a>]. Ischemic postconditioning appears to affect cardioprotection by activating survival protein kinases of the reperfusion-injury salvage kinase pathway [<a href="#rid105">105,106</a>]. Postconditioning reduces the number of necrotic, apoptotic, and autophagic cells [<a href="#rid107">107</a>]. (See <a class="local">'Ischemic preconditioning'</a> above.)</p><p>Initial insights into the potential timing of ischemic postconditioning in humans were provided by a forearm model of ischemic postconditioning [<a href="#rid108">108</a>]. After 20 minutes of sustained forearm ischemia, and at the onset of 20 minutes of reperfusion, an ischemic postconditioning protocol was applied comprising three 10- or 30-second cycles of alternate ischemia and reperfusion. Ischemic postconditioning improved endothelial function. No protection was observed if application of the postconditioning protocol was delayed for one minute, a finding that supports preclinical studies in which the postconditioning protocol needs to be instituted within one minute of full reflow [<a href="#rid109">109</a>].</p><p>The potential clinical use of ischemic postconditioning is discussed separately. (See  <a class="medical medical_review" href="/d/html/1489.html" rel="external">"Myocardial ischemic conditioning: Clinical implications", section on 'Therapeutic applications'</a>.)</p><p class="headingAnchor" id="H494882352"><span class="h1">REMOTE ISCHEMIC CONDITIONING</span><span class="headingEndMark"> — </span>The major limitation of myocardial ischemic conditioning is that it requires a protective stimulus to be applied to the heart directly. However, it has been discovered that the heart can be protected against acute myocardial infarction by applying brief cycles of (reversible) ischemia and reperfusion to a vascular bed, organ, or tissue away from the heart, termed remote ischemic conditioning [<a href="#rid110">110-112</a>]. </p><p>The mechanism through which the cardioprotective stimulus is relayed from the remote organ or tissue to the heart is unclear, and neurogenic, hormonal, and systemic factors have been proposed. Furthermore, it has been shown that there may be a co-dependence of both neural and humoral pathways in the overall mechanism of this form of conditioning [<a href="#rid113">113</a>]. It has been suggested that a bloodborne transferable protective factor is released into the circulation in response to the remote ischemic preconditioning stimulus to the organ or tissue [<a href="#rid45">45,46,84,110</a>]. Potential mediators include:</p><p class="bulletIndent1"><span class="glyph">●</span>Neurogenic pathway involving the somato-sensory system, the spinal cord, and the autonomous nervous system: adenosine, bradykinin, and calcitonin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Humoral pathway (a circulating cardioprotective factor): opioids, endocannabinoids, and angiotensin-2 receptors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic pathway: suppression of proinflammatory genes, expression in leucocytes, and reduced neutrophilic adhesion.</p><p></p><p>Remote ischemic conditioning has been applied before (remote ischemic preconditioning), during (remote ischemic preconditioning), and after (remote ischemic postconditioning) the onset of sustained myocardial ischemia [<a href="#rid84">84</a>]. Crucially, the protective stimulus can be applied in a noninvasive manner using a cuff placed on the hind limb to induce brief cycles of ischemia and reperfusion to the limb, facilitating its application in the clinical setting.</p><p>These findings have been shown to be applicable to humans by simply inflating and deflating a blood pressure cuff placed on the upper arm or thigh to induce brief ischemia and reperfusion. In one report, three five-minute cycles of ischemia to one upper extremity prevented endothelial dysfunction induced by subsequent ischemia to the contralateral upper extremity [<a href="#rid114">114</a>]. The potential use of remote ischemic preconditioning has now been evaluated in the clinical setting. (See  <a class="medical medical_review" href="/d/html/1489.html" rel="external">"Myocardial ischemic conditioning: Clinical implications", section on 'Therapeutic applications'</a>.) </p><p class="headingAnchor" id="H183985101"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition –</strong> Ischemic conditioning describes an endogenous phenomenon, in which one or more brief episodes of nonlethal ischemia and reperfusion confer protection against a sustained lethal episode of ischemia and reperfusion. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conditioning ischemic stimulus </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing –</strong> The conditioning stimulus can be applied before (ischemic preconditioning), during (ischemic preconditioning) or after the onset of (ischemic postconditioning) ischemia, or at the transition from sustained ischemia to reperfusion. (See <a class="local">'Ischemic preconditioning'</a> above and <a class="local">'Ischemic postconditioning'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anatomic location –</strong> The conditioning stimulus can be applied either directly to the heart or to a distant organ or tissue (remote ischemic conditioning). (See <a class="local">'Remote ischemic conditioning'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic ischemic conditioning –</strong> Elucidation of the mechanistic pathways underlying ischemic conditioning has identified potential pharmacological cardioprotective strategies (pharmacological conditioning). (See <a class="local">'Mediators'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74:1124.</a></li><li><a class="nounderline abstract_t">Liu GS, Thornton J, Van Winkle DM, et al. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 1991; 84:350.</a></li><li><a class="nounderline abstract_t">Li Y, Kloner RA. The cardioprotective effects of ischemic 'preconditioning' are not mediated by adenosine receptors in rat hearts. Circulation 1993; 87:1642.</a></li><li><a class="nounderline abstract_t">Sumeray MS, Yellon DM. Characterisation and validation of a murine model of global ischaemia-reperfusion injury. Mol Cell Biochem 1998; 186:61.</a></li><li><a class="nounderline abstract_t">Schott RJ, Rohmann S, Braun ER, Schaper W. Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res 1990; 66:1133.</a></li><li><a class="nounderline abstract_t">Kloner RA, Yellon D. Does ischemic preconditioning occur in patients? J Am Coll Cardiol 1994; 24:1133.</a></li><li><a class="nounderline abstract_t">Cave AC, Hearse DJ. Ischaemic preconditioning and contractile function: studies with normothermic and hypothermic global ischaemia. J Mol Cell Cardiol 1992; 24:1113.</a></li><li><a class="nounderline abstract_t">Shiki K, Hearse DJ. Preconditioning of ischemic myocardium: reperfusion-induced arrhythmias. Am J Physiol 1987; 253:H1470.</a></li><li><a class="nounderline abstract_t">Vegh A, Komori S, Szekeres L, Parratt JR. Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats. Cardiovasc Res 1992; 26:487.</a></li><li><a class="nounderline abstract_t">Piot CA, Padmanaban D, Ursell PC, et al. Ischemic preconditioning decreases apoptosis in rat hearts in vivo. Circulation 1997; 96:1598.</a></li><li><a class="nounderline abstract_t">Li YW, Whittaker P, Kloner RA. The transient nature of the effect of ischemic preconditioning on myocardial infarct size and ventricular arrhythmia. Am Heart J 1992; 123:346.</a></li><li><a class="nounderline abstract_t">Murry CE, Richard VJ, Jennings RB, Reimer KA. Myocardial protection is lost before contractile function recovers from ischemic preconditioning. Am J Physiol 1991; 260:H796.</a></li><li><a class="nounderline abstract_t">Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 1993; 88:1264.</a></li><li><a class="nounderline abstract_t">Kuzuya T, Hoshida S, Yamashita N, et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 1993; 72:1293.</a></li><li><a class="nounderline abstract_t">Baxter GF, Goma FM, Yellon DM. Characterisation of the infarct-limiting effect of delayed preconditioning: timecourse and dose-dependency studies in rabbit myocardium. Basic Res Cardiol 1997; 92:159.</a></li><li><a class="nounderline abstract_t">Yellon DM, Baxter GF. A "second window of protection" or delayed preconditioning phenomenon: future horizons for myocardial protection? J Mol Cell Cardiol 1995; 27:1023.</a></li><li><a class="nounderline abstract_t">Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007; 59:418.</a></li><li><a class="nounderline abstract_t">Whittington HJ, Harding I, Stephenson CI, et al. Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovasc Res 2013; 99:694.</a></li><li><a class="nounderline abstract_t">Tsang A, Hausenloy DJ, Mocanu MM, et al. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 2005; 54:2360.</a></li><li><a class="nounderline abstract_t">Ferdinandy P, Hausenloy DJ, Heusch G, et al. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev 2014; 66:1142.</a></li><li><a class="nounderline abstract_t">Speechly-Dick ME, Baxter GF, Yellon DM. Ischaemic preconditioning protects hypertrophied myocardium. Cardiovasc Res 1994; 28:1025.</a></li><li><a class="nounderline abstract_t">Pantos CI, Davos CH, Carageorgiou HC, et al. Ischaemic preconditioning protects against myocardial dysfunction caused by ischaemia in isolated hypertrophied rat hearts. Basic Res Cardiol 1996; 91:444.</a></li><li><a class="nounderline abstract_t">Burns PG, Krunkenkamp IB, Calderone CA, et al. Is the preconditioning response conserved in senescent myocardium? Ann Thorac Surg 1996; 61:925.</a></li><li><a class="nounderline abstract_t">Abete P, Ferrara N, Cioppa A, et al. Preconditioning does not prevent postischemic dysfunction in aging heart. J Am Coll Cardiol 1996; 27:1777.</a></li><li><a class="nounderline abstract_t">Tani M, Suganuma Y, Hasegawa H, et al. Changes in ischemic tolerance and effects of ischemic preconditioning in middle-aged rat hearts. Circulation 1997; 95:2559.</a></li><li><a class="nounderline abstract_t">Schulz R, Post H, Vahlhaus C, Heusch G. Ischemic preconditioning in pigs: a graded phenomenon: its relation to adenosine and bradykinin. Circulation 1998; 98:1022.</a></li><li><a class="nounderline abstract_t">Yamasaki K, Fujiwara H, Tanaka M, et al. Preconditioning with 15-minute ischemia extends myocardial infarct size after subsequent 30-minute ischemia in rabbits. Jpn Circ J 1997; 61:344.</a></li><li><a class="nounderline abstract_t">Figueras J, Segura R, Bermejo B. Repeated 15-minute coronary occlusions in pigs increase occlusion arrhythmias but decrease reperfusion arrhythmias that are associated with extracellular hypokalemia. J Am Coll Cardiol 1996; 28:1589.</a></li><li><a class="nounderline abstract_t">Hausenloy DJ. Cardioprotection techniques: preconditioning, postconditioning and remote conditioning (basic science). Curr Pharm Des 2013; 19:4544.</a></li><li><a class="nounderline abstract_t">Li Y, Kloner RA. Cardioprotective effects of ischaemic preconditioning are not mediated by prostanoids. Cardiovasc Res 1992; 26:226.</a></li><li><a class="nounderline abstract_t">Asimakis GK, Inners-McBride K, Medellin G, Conti VR. Ischemic preconditioning attenuates acidosis and postischemic dysfunction in isolated rat heart. Am J Physiol 1992; 263:H887.</a></li><li><a class="nounderline abstract_t">Matsuda M, Catena TG, Vander Heide RS, et al. Cardiac protection by ischaemic preconditioning is not mediated by myocardial stunning. Cardiovasc Res 1993; 27:585.</a></li><li><a class="nounderline abstract_t">de Albuquerque CP, Gerstenblith G, Weiss RG. Importance of metabolic inhibition and cellular pH in mediating preconditioning contractile and metabolic effects in rat hearts. Circ Res 1994; 74:139.</a></li><li><a class="nounderline abstract_t">Soares PR, de Albuquerque CP, Chacko VP, et al. Role of preischemic glycogen depletion in the improvement of postischemic metabolic and contractile recovery of ischemia-preconditioned rat hearts. Circulation 1997; 96:975.</a></li><li><a class="nounderline abstract_t">Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1. Circulation 2001; 104:2981.</a></li><li><a class="nounderline abstract_t">Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2. Circulation 2001; 104:3158.</a></li><li><a class="nounderline abstract_t">Yao Z, Gross GJ. Acetylcholine mimics ischemic preconditioning via a glibenclamide-sensitive mechanism in dogs. Am J Physiol 1993; 264:H2221.</a></li><li><a class="nounderline abstract_t">Banerjee A, Locke-Winter C, Rogers KB, et al. Preconditioning against myocardial dysfunction after ischemia and reperfusion by an alpha 1-adrenergic mechanism. Circ Res 1993; 73:656.</a></li><li><a class="nounderline abstract_t">Liu Y, Tsuchida A, Cohen MV, Downey JM. Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol 1995; 27:883.</a></li><li><a class="nounderline abstract_t">Goto M, Liu Y, Yang XM, et al. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 1995; 77:611.</a></li><li><a class="nounderline abstract_t">Erikson JM, Velasco CE. Endothelin-1 and myocardial preconditioning. Am Heart J 1996; 132:84.</a></li><li><a class="nounderline abstract_t">Schultz JE, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res 1996; 78:1100.</a></li><li><a class="nounderline abstract_t">Baines CP, Goto M, Downey JM. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. J Mol Cell Cardiol 1997; 29:207.</a></li><li><a class="nounderline abstract_t">Morris SD, Yellon DM. Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart. J Am Coll Cardiol 1997; 29:1599.</a></li><li><a class="nounderline abstract_t">Kharbanda RK, Nielsen TT, Redington AN. Translation of remote ischaemic preconditioning into clinical practice. Lancet 2009; 374:1557.</a></li><li><a class="nounderline abstract_t">Kolh P. Remote ischaemic pre-conditioning in cardiac surgery: benefit or not? Eur Heart J 2014; 35:141.</a></li><li><a class="nounderline abstract_t">Mullane K, Bullough D. Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine. J Mol Cell Cardiol 1995; 27:1041.</a></li><li><a class="nounderline abstract_t">Vogt AM, Ando H, Arras M, Elsässer A. Lack of adenosine causes myocardial refractoriness. J Am Coll Cardiol 1998; 31:1134.</a></li><li><a class="nounderline abstract_t">Dana A, Baxter GF, Walker JM, Yellon DM. Prolonging the delayed phase of myocardial protection: repetitive adenosine A1 receptor activation maintains rabbit myocardium in a preconditioned state. J Am Coll Cardiol 1998; 31:1142.</a></li><li><a class="nounderline abstract_t">Downey JM, Cohen MV. Signal transduction in ischemic preconditioning. Z Kardiol 1995; 84 Suppl 4:77.</a></li><li><a class="nounderline abstract_t">Node K, Kitakaze M, Sato H, et al. Role of intracellular Ca2+ in activation of protein kinase C during ischemic preconditioning. Circulation 1997; 96:1257.</a></li><li><a class="nounderline abstract_t">Przyklenk K, Hata K, Kloner RA. Is calcium a mediator of infarct size reduction with preconditioning in canine myocardium? Circulation 1997; 96:1305.</a></li><li><a class="nounderline abstract_t">Kitakaze M, Node K, Minamino T, et al. Role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5'-nucleotidase. Circulation 1996; 93:781.</a></li><li><a class="nounderline abstract_t">Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 1994; 266:H1145.</a></li><li><a class="nounderline abstract_t">Nakano A, Baines CP, Kim SO, et al. Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart: evidence for involvement of p38 MAPK. Circ Res 2000; 86:144.</a></li><li><a class="nounderline abstract_t">Sanada S, Asanuma H, Tsukamoto O, et al. Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C. Circulation 2004; 110:51.</a></li><li><a class="nounderline abstract_t">Baines CP, Wang L, Cohen MV, Downey JM. Protein tyrosine kinase is downstream of protein kinase C for ischemic preconditioning's anti-infarct effect in the rabbit heart. J Mol Cell Cardiol 1998; 30:383.</a></li><li><a class="nounderline abstract_t">Gross GJ, Mei DA, Schultz JJ, Mizumura T. Criteria for a mediator or effector of myocardial preconditioning: do KATP channels meet the requirements? Basic Res Cardiol 1996; 91:31.</a></li><li><a class="nounderline abstract_t">Sato T, Sasaki N, Seharaseyon J, et al. Selective pharmacological agents implicate mitochondrial but not sarcolemmal K(ATP) channels in ischemic cardioprotection. Circulation 2000; 101:2418.</a></li><li><a class="nounderline abstract_t">Minners J, van den Bos EJ, Yellon DM, et al. Dinitrophenol, cyclosporin A, and trimetazidine modulate preconditioning in the isolated rat heart: support for a mitochondrial role in cardioprotection. Cardiovasc Res 2000; 47:68.</a></li><li><a class="nounderline abstract_t">Schulz R, Rose J, Heusch G. Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine. Am J Physiol 1994; 267:H1341.</a></li><li><a class="nounderline abstract_t">Miura T, Kawamura S, Tatsuno H, et al. Ischemic preconditioning attenuates cardiac sympathetic nerve injury via ATP-sensitive potassium channels during myocardial ischemia. Circulation 2001; 104:1053.</a></li><li><a class="nounderline abstract_t">Jovanović A, Jovanović S, Lorenz E, Terzic A. Recombinant cardiac ATP-sensitive K+ channel subunits confer resistance to chemical hypoxia-reoxygenation injury. Circulation 1998; 98:1548.</a></li><li><a class="nounderline abstract_t">Ghosh S, Standen NB, Galiñianes M. Failure to precondition pathological human myocardium. J Am Coll Cardiol 2001; 37:711.</a></li><li><a class="nounderline abstract_t">Hu K, Duan D, Li GR, Nattel S. Protein kinase C activates ATP-sensitive K+ current in human and rabbit ventricular myocytes. Circ Res 1996; 78:492.</a></li><li><a class="nounderline abstract_t">Liu Y, Gao WD, O'Rourke B, Marban E. Synergistic modulation of ATP-sensitive K+ currents by protein kinase C and adenosine. Implications for ischemic preconditioning. Circ Res 1996; 78:443.</a></li><li><a class="nounderline abstract_t">Sato T, Sasaki N, O'Rourke B, Marbán E. Adenosine primes the opening of mitochondrial ATP-sensitive potassium channels: a key step in ischemic preconditioning? Circulation 2000; 102:800.</a></li><li><a class="nounderline abstract_t">Bell SP, Sack MN, Patel A, et al. Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J Am Coll Cardiol 2000; 36:2296.</a></li><li><a class="nounderline abstract_t">Schultz JE, Rose E, Yao Z, Gross GJ. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 1995; 268:H2157.</a></li><li><a class="nounderline abstract_t">Schultz JJ, Hsu AK, Gross GJ. Ischemic preconditioning is mediated by a peripheral opioid receptor mechanism in the intact rat heart. J Mol Cell Cardiol 1997; 29:1355.</a></li><li><a class="nounderline abstract_t">McPherson BC, Yao Z. Morphine mimics preconditioning via free radical signals and mitochondrial K(ATP) channels in myocytes. Circulation 2001; 103:290.</a></li><li><a class="nounderline abstract_t">Liang BT, Gross GJ. Direct preconditioning of cardiac myocytes via opioid receptors and KATP channels. Circ Res 1999; 84:1396.</a></li><li><a class="nounderline abstract_t">Vanden Hoek TL, Becker LB, Shao Z, et al. Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes. J Biol Chem 1998; 273:18092.</a></li><li><a class="nounderline abstract_t">Samavati L, Monick MM, Sanlioglu S, et al. Mitochondrial K(ATP) channel openers activate the ERK kinase by an oxidant-dependent mechanism. Am J Physiol Cell Physiol 2002; 283:C273.</a></li><li><a class="nounderline abstract_t">Yue Y, Krenz M, Cohen MV, et al. Menadione mimics the infarct-limiting effect of preconditioning in isolated rat hearts. Am J Physiol Heart Circ Physiol 2001; 281:H590.</a></li><li><a class="nounderline abstract_t">Tritto I, D'Andrea D, Eramo N, et al. Oxygen radicals can induce preconditioning in rabbit hearts. Circ Res 1997; 80:743.</a></li><li><a class="nounderline abstract_t">Forbes RA, Steenbergen C, Murphy E. Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. Circ Res 2001; 88:802.</a></li><li><a class="nounderline abstract_t">Crestanello JA, Lingle DM, Kamelgard J, et al. Ischemic preconditioning decreases oxidative stress during reperfusion: a chemiluminescence study. J Surg Res 1996; 65:53.</a></li><li><a class="nounderline abstract_t">Tong H, Chen W, Steenbergen C, Murphy E. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res 2000; 87:309.</a></li><li><a class="nounderline abstract_t">Krieg T, Cui L, Qin Q, et al. Mitochondrial ROS generation following acetylcholine-induced EGF receptor transactivation requires metalloproteinase cleavage of proHB-EGF. J Mol Cell Cardiol 2004; 36:435.</a></li><li><a class="nounderline abstract_t">Krieg T, Qin Q, Philipp S, et al. Acetylcholine and bradykinin trigger preconditioning in the heart through a pathway that includes Akt and NOS. Am J Physiol Heart Circ Physiol 2004; 287:H2606.</a></li><li><a class="nounderline abstract_t">Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 2005; 288:H971.</a></li><li><a class="nounderline abstract_t">Strohm C, Barancik T, Brühl ML, et al. Inhibition of the ER-kinase cascade by PD98059 and UO126 counteracts ischemic preconditioning in pig myocardium. J Cardiovasc Pharmacol 2000; 36:218.</a></li><li><a class="nounderline abstract_t">Heusch G, Bøtker HE, Przyklenk K, et al. Remote ischemic conditioning. J Am Coll Cardiol 2015; 65:177.</a></li><li><a class="nounderline abstract_t">Oldenburg O, Qin Q, Krieg T, et al. Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. Am J Physiol Heart Circ Physiol 2004; 286:H468.</a></li><li><a class="nounderline abstract_t">Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 2002; 55:534.</a></li><li><a class="nounderline abstract_t">Juhaszova M, Zorov DB, Kim SH, et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004; 113:1535.</a></li><li><a class="nounderline abstract_t">Hausenloy DJ, Lecour S, Yellon DM. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal 2011; 14:893.</a></li><li><a class="nounderline abstract_t">Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995; 307 ( Pt 1):93.</a></li><li><a class="nounderline abstract_t">Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999; 341 ( Pt 2):233.</a></li><li><a class="nounderline abstract_t">Kaeffer N, Richard V, Thuillez C. Delayed coronary endothelial protection 24 hours after preconditioning: role of free radicals. Circulation 1997; 96:2311.</a></li><li><a class="nounderline abstract_t">Baxter GF, Marber MS, Patel VC, Yellon DM. Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning. Circulation 1994; 90:2993.</a></li><li><a class="nounderline abstract_t">Dana A, Jonassen AK, Yamashita N, Yellon DM. Adenosine A(1) receptor activation induces delayed preconditioning in rats mediated by manganese superoxide dismutase. Circulation 2000; 101:2841.</a></li><li><a class="nounderline abstract_t">Takano H, Manchikalapudi S, Tang XL, et al. Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. Circulation 1998; 98:441.</a></li><li><a class="nounderline abstract_t">Guo Y, Jones WK, Xuan YT, et al. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci U S A 1999; 96:11507.</a></li><li><a class="nounderline abstract_t">Sun JZ, Tang XL, Park SW, et al. Evidence for an essential role of reactive oxygen species in the genesis of late preconditioning against myocardial stunning in conscious pigs. J Clin Invest 1996; 97:562.</a></li><li><a class="nounderline abstract_t">Bolli R, Bhatti ZA, Tang XL, et al. Evidence that late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide. Circ Res 1997; 81:42.</a></li><li><a class="nounderline abstract_t">Sasaki N, Sato T, Ohler A, et al. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 2000; 101:439.</a></li><li><a class="nounderline abstract_t">Vegh A, Papp JG, Parratt JR. Prevention by dexamethasone of the marked antiarrhythmic effects of preconditioning induced 20 h after rapid cardiac pacing. Br J Pharmacol 1994; 113:1081.</a></li><li><a class="nounderline abstract_t">Bolli R, Shinmura K, Tang XL, et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 2002; 55:506.</a></li><li><a class="nounderline abstract_t">Shinmura K, Tang XL, Wang Y, et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A 2000; 97:10197.</a></li><li><a class="nounderline abstract_t">Shinmura K, Xuan YT, Tang XL, et al. Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res 2002; 90:602.</a></li><li><a class="nounderline abstract_t">Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285:H579.</a></li><li><a class="nounderline abstract_t">Argaud L, Gateau-Roesch O, Raisky O, et al. Postconditioning inhibits mitochondrial permeability transition. Circulation 2005; 111:194.</a></li><li><a class="nounderline abstract_t">Yang XM, Proctor JB, Cui L, et al. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 2004; 44:1103.</a></li><li><a class="nounderline abstract_t">Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 2004; 95:230.</a></li><li><a class="nounderline abstract_t">Zhao ZQ, Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res 2006; 70:200.</a></li><li><a class="nounderline abstract_t">Loukogeorgakis SP, Panagiotidou AT, Yellon DM, et al. Postconditioning protects against endothelial ischemia-reperfusion injury in the human forearm. Circulation 2006; 113:1015.</a></li><li><a class="nounderline abstract_t">Tsang A, Hausenloy DJ, Yellon DM. Myocardial postconditioning: reperfusion injury revisited. Am J Physiol Heart Circ Physiol 2005; 289:H2.</a></li><li><a class="nounderline abstract_t">Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res 2008; 79:377.</a></li><li><a class="nounderline abstract_t">Bell R, Yellon D. Surgery: Remote ischaemic conditioning--approaching prime time? Nat Rev Cardiol 2013; 10:619.</a></li><li><a class="nounderline abstract_t">Rossello X, Riquelme JA, He Z, et al. The role of PI3Kα isoform in cardioprotection. Basic Res Cardiol 2017; 112:66.</a></li><li><a class="nounderline abstract_t">Pickard JM, Davidson SM, Hausenloy DJ, Yellon DM. Co-dependence of the neural and humoral pathways in the mechanism of remote ischemic conditioning. Basic Res Cardiol 2016; 111:50.</a></li><li><a class="nounderline abstract_t">Kharbanda RK, Mortensen UM, White PA, et al. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation 2002; 106:2881.</a></li></ol></div><div id="topicVersionRevision">Topic 1487 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3769170" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2060105" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8491020" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The cardioprotective effects of ischemic 'preconditioning' are not mediated by adenosine receptors in rat hearts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9774186" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Characterisation and validation of a murine model of global ischaemia-reperfusion injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2317890" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ischemic preconditioning reduces infarct size in swine myocardium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7930208" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Does ischemic preconditioning occur in patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1479613" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ischaemic preconditioning and contractile function: studies with normothermic and hypothermic global ischaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3425747" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Preconditioning of ischemic myocardium: reperfusion-induced arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1446318" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9315553" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Ischemic preconditioning decreases apoptosis in rat hearts in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1736569" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The transient nature of the effect of ischemic preconditioning on myocardial infarct size and ventricular arrhythmia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2000974" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Myocardial protection is lost before contractile function recovers from ischemic preconditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8353888" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8495557" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9226101" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Characterisation of the infarct-limiting effect of delayed preconditioning: timecourse and dose-dependency studies in rabbit myocardium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7563099" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A "second window of protection" or delayed preconditioning phenomenon: future horizons for myocardial protection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18048761" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23723063" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16046302" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Preconditioning the diabetic heart: the importance of Akt phosphorylation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25261534" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7954588" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ischaemic preconditioning protects hypertrophied myocardium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996629" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ischaemic preconditioning protects against myocardial dysfunction caused by ischaemia in isolated hypertrophied rat hearts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8619719" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Is the preconditioning response conserved in senescent myocardium?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636568" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Preconditioning does not prevent postischemic dysfunction in aging heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9184587" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Changes in ischemic tolerance and effects of ischemic preconditioning in middle-aged rat hearts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9737523" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Ischemic preconditioning in pigs: a graded phenomenon: its relation to adenosine and bradykinin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9152787" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Preconditioning with 15-minute ischemia extends myocardial infarct size after subsequent 30-minute ischemia in rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8917276" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Repeated 15-minute coronary occlusions in pigs increase occlusion arrhythmias but decrease reperfusion arrhythmias that are associated with extracellular hypokalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23270554" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cardioprotection techniques: preconditioning, postconditioning and remote conditioning (basic science).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1423416" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cardioprotective effects of ischaemic preconditioning are not mediated by prostanoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1415616" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ischemic preconditioning attenuates acidosis and postischemic dysfunction in isolated rat heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8324790" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cardiac protection by ischaemic preconditioning is not mediated by myocardial stunning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8261587" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Importance of metabolic inhibition and cellular pH in mediating preconditioning contractile and metabolic effects in rat hearts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9264509" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Role of preischemic glycogen depletion in the improvement of postischemic metabolic and contractile recovery of ischemia-preconditioned rat hearts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739316" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11748117" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8322953" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Acetylcholine mimics ischemic preconditioning via a glibenclamide-sensitive mechanism in dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8396503" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Preconditioning against myocardial dysfunction after ischemia and reperfusion by an alpha 1-adrenergic mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7602606" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7641331" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Role of bradykinin in protection of ischemic preconditioning in rabbit hearts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8701880" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Endothelin-1 and myocardial preconditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8635241" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9040035" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9180125" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19880021" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Translation of remote ischaemic preconditioning into clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24394382" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Remote ischaemic pre-conditioning in cardiac surgery: benefit or not?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7563101" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9562019" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Lack of adenosine causes myocardial refractoriness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9562020" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prolonging the delayed phase of myocardial protection: repetitive adenosine A1 receptor activation maintains rabbit myocardium in a preconditioned state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8585277" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Signal transduction in ischemic preconditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9286957" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Role of intracellular Ca2+ in activation of protein kinase C during ischemic preconditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9286963" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Is calcium a mediator of infarct size reduction with preconditioning in canine myocardium?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8641008" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5'-nucleotidase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8160817" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Preconditioning protects ischemic rabbit heart by protein kinase C activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10666409" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart: evidence for involvement of p38 MAPK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15210595" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9515015" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Protein tyrosine kinase is downstream of protein kinase C for ischemic preconditioning's anti-infarct effect in the rabbit heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8660253" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Criteria for a mediator or effector of myocardial preconditioning: do KATP channels meet the requirements?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10821820" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Selective pharmacological agents implicate mitochondrial but not sarcolemmal K(ATP) channels in ischemic cardioprotection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10869531" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Dinitrophenol, cyclosporin A, and trimetazidine modulate preconditioning in the isolated rat heart: support for a mitochondrial role in cardioprotection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7943380" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11524401" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ischemic preconditioning attenuates cardiac sympathetic nerve injury via ATP-sensitive potassium channels during myocardial ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9769309" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Recombinant cardiac ATP-sensitive K+ channel subunits confer resistance to chemical hypoxia-reoxygenation injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11693741" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Failure to precondition pathological human myocardium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8593708" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Protein kinase C activates ATP-sensitive K+ current in human and rabbit ventricular myocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8593703" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Synergistic modulation of ATP-sensitive K+ currents by protein kinase C and adenosine. Implications for ischemic preconditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942750" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Adenosine primes the opening of mitochondrial ATP-sensitive potassium channels: a key step in ischemic preconditioning?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11127476" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7771566" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9201621" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Ischemic preconditioning is mediated by a peripheral opioid receptor mechanism in the intact rat heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11208691" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Morphine mimics preconditioning via free radical signals and mitochondrial K(ATP) channels in myocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10381891" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Direct preconditioning of cardiac myocytes via opioid receptors and KATP channels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9660766" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12055096" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Mitochondrial K(ATP) channel openers activate the ERK kinase by an oxidant-dependent mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11454561" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Menadione mimics the infarct-limiting effect of preconditioning in isolated rat hearts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9130455" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Oxygen radicals can induce preconditioning in rabbit hearts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11325872" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8895606" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Ischemic preconditioning decreases oxidative stress during reperfusion: a chemiluminescence study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10948065" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15010282" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Mitochondrial ROS generation following acetylcholine-induced EGF receptor transactivation requires metalloproteinase cleavage of proHB-EGF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15331366" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Acetylcholine and bradykinin trigger preconditioning in the heart through a pathway that includes Akt and NOS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15358610" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Ischemic preconditioning protects by activating prosurvival kinases at reperfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942164" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Inhibition of the ER-kinase cascade by PD98059 and UO126 counteracts ischemic preconditioning in pig myocardium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25593060" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Remote ischemic conditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12958031" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12160950" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15173880" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20615076" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7717999" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10393078" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The mitochondrial permeability transition pore and its role in cell death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9337205" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Delayed coronary endothelial protection 24 hours after preconditioning: role of free radicals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7994847" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10859291" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Adenosine A(1) receptor activation induces delayed preconditioning in rats mediated by manganese superoxide dismutase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9714095" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10500207" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8567981" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Evidence for an essential role of reactive oxygen species in the genesis of late preconditioning against myocardial stunning in conscious pigs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9201026" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Evidence that late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10653837" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Activation of mitochondrial ATP-dependent potassium channels by nitric oxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7889255" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Prevention by dexamethasone of the marked antiarrhythmic effects of preconditioning induced 20 h after rapid cardiac pacing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12160947" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10963682" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11909825" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860564" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15642769" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Postconditioning inhibits mitochondrial permeability transition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337225" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15242972" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16545349" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Postconditioning: reduction of reperfusion-induced injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16476844" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Postconditioning protects against endothelial ischemia-reperfusion injury in the human forearm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15961374" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Myocardial postconditioning: reperfusion injury revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18456674" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Remote ischaemic preconditioning: underlying mechanisms and clinical application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24060957" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Surgery: Remote ischaemic conditioning--approaching prime time?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29043508" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The role of PI3Kαisoform in cardioprotection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27338249" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Co-dependence of the neural and humoral pathways in the mechanism of remote ischemic conditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12460865" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Transient limb ischemia induces remote ischemic preconditioning in vivo.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
